Skip to main content
Erschienen in: PharmacoEconomics 5/2012

01.05.2012 | Original Research Article

Changes in Antipsychotic Medication Use after Implementation of a Medicaid Mental Health Carve-Out in the US

verfasst von: Dr John Robst

Erschienen in: PharmacoEconomics | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Background: Many Medicaid programmes now offer behavioural healthcare through managed care organizations. Medicaid programmes are concerned about carve-outs because the use of non-included services may rise, limiting the efficiencies anticipated with the implementation of managed care. There also exist concerns that patients with serious mental illness may receive reduced care through managed care and consequently have poorer outcomes.
Objective: This study examined prescription drug utilization among Medicaid recipients with the implementation of a mental health carve-out plan in Florida. In particular, this study examined short-run changes in the utilization of antipsychotic medications among individuals diagnosed with schizophrenia or episodic mood disorders with the implementation of Prepaid Mental Health Plans (PMHPs) in Florida Medicaid.
Methods: This study used Medicaid data from 38 counties in Florida that implemented the PMHP programme in 2005 and 2006. The sample was limited to individuals aged ≤64 years who were continuously enrolled in Medicaid. Individuals were required to have at least two diagnoses of schizophrenia, episodic mood disorders, delusional disorders or other nonorganic disorders (three-digit International Classification of Diseases, Ninth Revision [ICD-9] code of 295–298).
Five different outcome measures were examined on a monthly basis for the 6 months pre–and post–PMHP implementation: penetration; adherence; Medicaid expenditures for antipsychotics; polypharmacy (multiple antipsychotic medications); and whether dosing was within guidelines. Generalized estimating equations were used to estimate associations between individual and insurance characteristics, and the outcome variables. The analyses were conducted using SAS procedure GENMOD. Empirical (robust) standard errors were calculated to account for repeated observations on the same individual.
Results: There were 153 720 monthly observations for the 12 810 people in the sample. Seventy-four percent of the sample was aged between 21 and 54 years, while 65% were female, 30% White, 14% Black and 44% Hispanic. The large proportion of Hispanics stems from the introduction of the PMHP programme in Dade County (Miami).
The results indicate the implementation of the PMHP was associated with increased penetration, but reduced adherence, polypharmacy and expenditures by the Medicaid agency. There was no change in the likelihood of prescriptions being written within recommended dosage ranges.
Conclusion: The introduction of the PMHP was associated with short-run changes in medication utilization among individuals with serious mental illness.
Literatur
1.
Zurück zum Zitat Haslanger K, Tallon Jr J. Medicaid managed care: there’s more for states to do. Manag Care Q 2004; 12: 1–5PubMed Haslanger K, Tallon Jr J. Medicaid managed care: there’s more for states to do. Manag Care Q 2004; 12: 1–5PubMed
2.
Zurück zum Zitat Holahan J, Rangarajan S, Schirmer M. Medicaid managed care payment rates in 1998. Health Aff 1999; 18: 217–27CrossRef Holahan J, Rangarajan S, Schirmer M. Medicaid managed care payment rates in 1998. Health Aff 1999; 18: 217–27CrossRef
3.
Zurück zum Zitat Cutler D, McClellan M, Newhouse J. How does managed care do it? Rand J Econ 2000; 31: 526–48PubMedCrossRef Cutler D, McClellan M, Newhouse J. How does managed care do it? Rand J Econ 2000; 31: 526–48PubMedCrossRef
4.
Zurück zum Zitat Tohen M, Vieta E. Antipsychotic agents in the treatment of bipolar mania. Bipolar Dis 2009; 11: 45–54CrossRef Tohen M, Vieta E. Antipsychotic agents in the treatment of bipolar mania. Bipolar Dis 2009; 11: 45–54CrossRef
5.
Zurück zum Zitat Nelson JG, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166: 980–91PubMedCrossRef Nelson JG, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166: 980–91PubMedCrossRef
6.
Zurück zum Zitat Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large healthplandatabase. J Clin Psychiatry 2002; 63: 920–30PubMedCrossRef Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large healthplandatabase. J Clin Psychiatry 2002; 63: 920–30PubMedCrossRef
7.
Zurück zum Zitat Rosenheck RA. Open forum. Effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator. Psychiatr Serv 2005; 56: 85–92 Rosenheck RA. Open forum. Effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator. Psychiatr Serv 2005; 56: 85–92
8.
Zurück zum Zitat Tandon R, Fleischhacker WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 2005; 79: 145–55PubMedCrossRef Tandon R, Fleischhacker WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 2005; 79: 145–55PubMedCrossRef
9.
Zurück zum Zitat Patel N, Crismon L, Hoagwood K. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 2005; 44: 548–56PubMedCrossRef Patel N, Crismon L, Hoagwood K. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 2005; 44: 548–56PubMedCrossRef
10.
Zurück zum Zitat Rascati KL, Johnsrud MT, Crismon ML, et al. Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid recipients. Pharmacoeconomics 2003; 21 (10): 683–97PubMedCrossRef Rascati KL, Johnsrud MT, Crismon ML, et al. Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid recipients. Pharmacoeconomics 2003; 21 (10): 683–97PubMedCrossRef
11.
Zurück zum Zitat Eaddy M, Grogg A, Locklear J. Assessment of adherence with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 2005; 27: 263–72PubMedCrossRef Eaddy M, Grogg A, Locklear J. Assessment of adherence with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 2005; 27: 263–72PubMedCrossRef
12.
Zurück zum Zitat Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs firstgeneration antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079–87PubMedCrossRef Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs firstgeneration antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079–87PubMedCrossRef
13.
Zurück zum Zitat Thieda P, Beard S, Richter A, et al. An economic review of adherence with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003; 54: 508–16PubMedCrossRef Thieda P, Beard S, Richter A, et al. An economic review of adherence with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003; 54: 508–16PubMedCrossRef
14.
Zurück zum Zitat Weiden PJ, Kozma C, Grogg A, et al. Partial adherence and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004; 55: 886–91PubMedCrossRef Weiden PJ, Kozma C, Grogg A, et al. Partial adherence and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004; 55: 886–91PubMedCrossRef
15.
Zurück zum Zitat Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159: 103–8PubMedCrossRef Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159: 103–8PubMedCrossRef
16.
Zurück zum Zitat Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63: 892–909PubMedCrossRef Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63: 892–909PubMedCrossRef
17.
18.
Zurück zum Zitat Wallace NT, Bloom JR, Hu TW, et al. Medication treatment patterns for adults with schizophrenia in Medicaid managed care in Colorado. Psychiatr Serv 2005; 56: 1402–8PubMedCrossRef Wallace NT, Bloom JR, Hu TW, et al. Medication treatment patterns for adults with schizophrenia in Medicaid managed care in Colorado. Psychiatr Serv 2005; 56: 1402–8PubMedCrossRef
19.
Zurück zum Zitat Azocar F, Cuffel BD, Goldman W, et al. Dissemination of guidelines for the treatment of major depression in a managed behavioral health care network. Psychiatr Serv 2001; 52 (8): 1014–6PubMedCrossRef Azocar F, Cuffel BD, Goldman W, et al. Dissemination of guidelines for the treatment of major depression in a managed behavioral health care network. Psychiatr Serv 2001; 52 (8): 1014–6PubMedCrossRef
20.
Zurück zum Zitat Dickey B, Normand ST, Hermann RC, et al. Guideline recommendations for treatment of schizophrenia. Arch Gen Psychiatry 2003; 60: 340–8PubMedCrossRef Dickey B, Normand ST, Hermann RC, et al. Guideline recommendations for treatment of schizophrenia. Arch Gen Psychiatry 2003; 60: 340–8PubMedCrossRef
21.
Zurück zum Zitat Ray WA, Daugherty JR, Meador KG. Effect of a mental health “carve-out” program on the continuity of antipsychotic therapy. N Engl J Med 2003; 348: 1885–94PubMedCrossRef Ray WA, Daugherty JR, Meador KG. Effect of a mental health “carve-out” program on the continuity of antipsychotic therapy. N Engl J Med 2003; 348: 1885–94PubMedCrossRef
22.
Zurück zum Zitat Popkin MK, Lurie N, Manning W, et al. Changes in the process of care for Medicaid patients with schizophrenia in Utah’s prepaid mental health plan. Psychiatr Serv 1998; 49: 518–23PubMed Popkin MK, Lurie N, Manning W, et al. Changes in the process of care for Medicaid patients with schizophrenia in Utah’s prepaid mental health plan. Psychiatr Serv 1998; 49: 518–23PubMed
23.
Zurück zum Zitat Ridgely S, Giard J, Shern D. Florida’s Medicaid mental health carve-out. J Behav Health Serv Res 1999; 26: 400–15PubMedCrossRef Ridgely S, Giard J, Shern D. Florida’s Medicaid mental health carve-out. J Behav Health Serv Res 1999; 26: 400–15PubMedCrossRef
24.
Zurück zum Zitat Constantine RJ, Murrin MR, Dhont K, et al. Developing and testing new methods for the administrative data component of the managed behavioral health care evaluation in Florida. Tampa (FL): University of South Florida, 2006 Constantine RJ, Murrin MR, Dhont K, et al. Developing and testing new methods for the administrative data component of the managed behavioral health care evaluation in Florida. Tampa (FL): University of South Florida, 2006
25.
Zurück zum Zitat Soumerai S, Zhang F, Ross-Degnan D, et al. Use of atypical drugs for schizophrenia in Maine following a policy change. Health Aff 2008; 27: 185–95CrossRef Soumerai S, Zhang F, Ross-Degnan D, et al. Use of atypical drugs for schizophrenia in Maine following a policy change. Health Aff 2008; 27: 185–95CrossRef
26.
Zurück zum Zitat Valenstein M, Copeland LA, McCarthy JF, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004; 30: 255–64PubMedCrossRef Valenstein M, Copeland LA, McCarthy JF, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004; 30: 255–64PubMedCrossRef
27.
Zurück zum Zitat Gilmer TP, Dolder CR, Folsom DP, et al. Antipsychotic polypharmacy trends among Medi-Cal beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatr Serv 2007; 58: 1007–10PubMedCrossRef Gilmer TP, Dolder CR, Folsom DP, et al. Antipsychotic polypharmacy trends among Medi-Cal beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatr Serv 2007; 58: 1007–10PubMedCrossRef
28.
Zurück zum Zitat Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations, 2003. Schizophr Bull 2004; 30: 193–217PubMedCrossRef Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations, 2003. Schizophr Bull 2004; 30: 193–217PubMedCrossRef
29.
Zurück zum Zitat Hardin J, Hilbe J. Generalized estimating equations. Danvers (MA): CRC Press, 2002CrossRef Hardin J, Hilbe J. Generalized estimating equations. Danvers (MA): CRC Press, 2002CrossRef
Metadaten
Titel
Changes in Antipsychotic Medication Use after Implementation of a Medicaid Mental Health Carve-Out in the US
verfasst von
Dr John Robst
Publikationsdatum
01.05.2012
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 5/2012
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/11539830-000000000-00000

Weitere Artikel der Ausgabe 5/2012

PharmacoEconomics 5/2012 Zur Ausgabe

Correspondence

The Authors’ Reply